Loading...
Loading...
Cubist Pharmaceuticals, Inc.
CBST and Adynxx, Inc. announced today
that they have entered into an option agreement under which Cubist has the
exclusive right to acquire Adynxx following the data readout of Adynxx's Phase
2 trial for its lead product candidate, AYX1.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
